Research Keyword: psychiatric disorders

Exploring Molecular Changes in the Extended Amygdala Induced by Chronic Corticosterone Administration

mycolabadmin

Researchers studied how prolonged stress hormone exposure affects the brain’s emotional center in mice. They found that chronic corticosterone treatment caused depression-like behaviors and specific molecular changes in different parts of the amygdala, a brain region crucial for processing emotions. These findings help explain how chronic stress disrupts the brain’s normal stress-regulation system and contributes to depression and other psychiatric conditions.

Read More »

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models

mycolabadmin

This paper addresses confusion about how ketamine and psychedelics are being used to treat mental health conditions like depression and PTSD. The authors propose new clear definitions to distinguish whether these drugs are used alone for their chemical effects, combined with established talk therapies, or used to create experiences that are then processed in therapy. Using these clearer definitions will help patients, doctors, and regulators better understand what treatments involve and make more informed decisions.

Read More »

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

mycolabadmin

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Read More »

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

mycolabadmin

This review examines how psilocybin, the active compound in magic mushrooms, may help treat difficult-to-treat conditions like smoking addiction, alcohol dependence, and depression. Clinical trials show psilocybin-assisted therapy achieves better smoking cessation rates (80%) than standard medications and reduces depression symptoms as effectively as common antidepressants. The treatment works differently than daily medications, requiring only a few supervised doses weeks apart, potentially offering a new option for millions of people.

Read More »

Identification of a psychiatric risk gene NISCH at 3p21.1 GWAS locus mediating dendritic spine morphogenesis and cognitive function

mycolabadmin

Researchers identified a gene called NISCH that increases the risk of schizophrenia and bipolar disorder. When this gene is overactive, it changes the shape of connections between brain cells and impairs working memory in mice. Interestingly, blood pressure medications like clonidine can reduce NISCH activity and improve cognitive function, suggesting these drugs might help psychiatric patients.

Read More »

Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus

mycolabadmin

Researchers studied how a protein called erythropoietin (EPO) affects brain cells called interneurons in the hippocampus, a region important for memory and learning. They found that EPO treatment reduces the inhibitory activity of certain interneurons, which makes the brain’s excitatory neurons more active. This change in brain balance could potentially help treat psychiatric disorders like schizophrenia and autism that involve imbalanced brain activity.

Read More »
Scroll to Top